Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Boehringer Ingelheim
McKesson
Medtronic
Harvard Business School

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

NERLYNX Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Nerlynx, and what generic alternatives are available?

Nerlynx is a drug marketed by Puma Biotech and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and six patent family members in twenty-one countries.

The generic ingredient in NERLYNX is neratinib maleate. One supplier is listed for this compound. Additional details are available on the neratinib maleate profile page.

Summary for NERLYNX
Drug patent expirations by year for NERLYNX
Drug Prices for NERLYNX

See drug prices for NERLYNX

Generic Entry Opportunity Date for NERLYNX
Generic Entry Date for NERLYNX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NERLYNX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Puma Biotechnology, Inc.Phase 1/Phase 2
Virginia Commonwealth UniversityPhase 1/Phase 2
NSABP Foundation IncPhase 2

See all NERLYNX clinical trials

Pharmacology for NERLYNX
Synonyms for NERLYNX
(2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
(2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide neratinib
(2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
(2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;HKI-272
(E)-N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
(E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylami
(E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
(E)-N-[4-[3-chloro-4-(2-pyridylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolyl]-4-(dimethylamino)but-2-enamide
2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-
387N096
4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide
698387-09-6
698387-09-6, HKI272, HKI 272, HKI-272,
736156-77-7
A25338
AB0008022
ABP000871
AC-25073
AK170454
AKOS005146340
AKOS025149637
AN-546
AOB87125
AS-16279
BC256322
BCP9000984
BCPP000151
BDBM50161957
BIFK0031
BRD-K85606544-001-01-8
C30H29ClN6O3
cc-32
CDP-820
CHEMBL180022
D08950
DB11828
DTXSID70220132
EX-A062
GTPL5686
HKI 272
HKI-272
HY-32721
I06-2375
JJH94R3PWB
JSPY-st000262
KB-58129
MolPort-006-069-389
N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
NCGC00241101-01
NCGC00241101-03
Neratinib
Neratinib - HKI-272
Neratinib (HKI-272)
Neratinib (USAN/INN)
Neratinib [USAN:INN]
Neratinib HKI 272
Neratinib(HKI-272)
Neratinib(HKI-272)/HKI272
PB 272
PB-272
PubChem22399
Q-101402
QCR-104
RL04677
s2150
SB16595
SC-28031
SCHEMBL571762
SCHEMBL571763
SYN1140
Tube708
UNII-JJH94R3PWB
WAY-179272
WAY-179272-B
X2638
Z-3202
ZINC3916214
ZX-AFC000299

US Patents and Regulatory Information for NERLYNX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Puma Biotech NERLYNX neratinib maleate TABLET;ORAL 208051-001 Jul 17, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Puma Biotech NERLYNX neratinib maleate TABLET;ORAL 208051-001 Jul 17, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Puma Biotech NERLYNX neratinib maleate TABLET;ORAL 208051-001 Jul 17, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Puma Biotech NERLYNX neratinib maleate TABLET;ORAL 208051-001 Jul 17, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Puma Biotech NERLYNX neratinib maleate TABLET;ORAL 208051-001 Jul 17, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Puma Biotech NERLYNX neratinib maleate TABLET;ORAL 208051-001 Jul 17, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Colorcon
AstraZeneca
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.